mTOR Pathway Substrates Present High Activation in Vascular Malformations and Significantly Decrease with Age.

Background: Vascular anomalies often result in aesthetic flaws, pain, and impair the quality of life. They require challenging treatments that frequently do not provide the desired results. The mammalian target of rapamycin (mTOR) is directly involved in the development of these malformations.